Burkitt's acute lymphocytic leukemia (L3ALL) in adults.
Burkitt's acute lymphocytic leukemia is a rare type of adult ALL, probably difficult to distinguish from disseminated Burkitt's lymphoma involving the bone marrow. This tumor is highly proliferative and tends to involve the CNS at diagnosis or early during the disease course. It shows rapid chemosensitivity, initially leading to the risk of severe acute tumor lysis syndrome. Principles of its treatment, by comparison with the other types of ALL, include: 1. A low-dose chemotherapy prephase to prevent acute tumor lysis syndrome. 2. Multiagent chemotherapy using high-dose cyclophosphamide, an anthracycline, high-dose MTX, high-dose ara-C, and probably VP16. A short and intensive treatment (6 to 8 months) without maintenance is indicated. 3. Early intensive CNS treatment, with multiple triple intrathecal injections, high-dose MTX, and high-dose ara-C, and possibly cranial irradiation. Autologous or allogeneic stem cell transplantation do not seem to be useful in first CR. Using such approaches, recent results suggest that about two thirds of L3ALL in adults can be cured, more than in any other type of adult ALL.
Service des Maladies du Sang CHU, Lille, France.
P
P
Fenaux
J H
JH
Bourhis
V
V
Ribrag
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002051:Burkitt Lymphoma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy; D002490:Central Nervous System / Q000473:pathology; D002648:Child; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003937:Diagnosis, Differential; D018450:Disease Progression; D015658:HIV Infections / Q000150:complications; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017254:Leukemic Infiltration; D015337:Multicenter Studies as Topic; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D013921:Thrombocytopenia / Q000209:etiology; D016896:Treatment Outcome; D015275:Tumor Lysis Syndrome / Q000401:mortality